Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18015135 | 0.83 | CRHR1 (0.42) | NPC1RAB9APTGDR2MEN1KMT2A | |
| SCHEMBL1268164 | 0.77 | KMT2A (0.51) | NPC1HSD17B10RAB9APTGDR2MEN1 | |
| SCHEMBL20530837 | 0.75 | KMT2A (0.62) | NPC1RAB9APTGDR2MEN1KMT2A | |
| SCHEMBL18015148 | 0.74 | RAB9A (0.59) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL16398907 | 0.73 | HTR2B (0.51) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL16092998 | 0.69 | RAB9A (0.77) | NPC1HSD17B10RAB9AMEN1KMT2A | |
| SCHEMBL22293266 | 0.69 | PPARD (0.37) | NPC1 | |
| SCHEMBL30722030 | 0.68 | RAB9A (0.64) | NPC1HSD17B10RAB9AMEN1KMT2A | |
| SCHEMBL18015146 | 0.68 | CRHR1 (0.43) | NPC1RAB9APOLB | |
| SCHEMBL18975158 | 0.67 | MEN1 (0.45) | NPC1RAB9APTGDR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | NPC1 1062/4885HSD17B10 121/4885RAB9A 4775/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | NPC1 1062/4885HSD17B10 121/4885RAB9A 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.